Resultados de la búsqueda 311-320 of 12310 for Visceral leishmaniasis

  1. Smoldering multiple myeloma (SMM) - Diagnósticos y tratamientos - Mayo Clinic

    Changed plasma cells making up 10% to less than 60% of the cells in the bone marrow. For a diagnosis of SMM, you also mush not have light-chain amyloidosis or a ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

  4. Médicos y departamentos

    AskMayoExpert. Measles and measles vaccination FAQs. Mayo Clinic; 2025. Routine measles, mumps and rubella vaccination. Centers for Disease Control and ...

  5. Médicos y departamentos

    Papadakis MA, et al., eds. Varicose veins. In: Current Medical Diagnosis & Treatment 2023. 62nd ed. McGraw Hill; 2023. https://accessmedicine.mhmedical.com.

  6. Enfermedad mixta del tejido conectivo

    Enfermedad mixta del tejido conectivo · Ong V. Mixed connective tissue disease. · Mixed connective tissue disease. Merck Manual Professional Version.

  7. Cirugía - Ensayos clínicos - Mayo Clinic

    Cutaneous Tissue Using Ex Vivo Fluorescence Confocal Microscopy. Rochester ... cutaneous tissue for determination of non-melanoma skin cancer tumor ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...